Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dana Winrow who wrote (1486)	2/26/1998 10:49:00 AM
From: Dana Winrow	Respond to of 1894

I have just received the reprints of Dawn Grohs' article in the January-February 1998 Acta Cytologica entitled "Impact of Automated Technology on the Cervical Cytologic Smear: A Comparison of Cost". An abstract is available online: acta-cytol.com The article features a comparative cost analysis of various aspects of cervical cytologic screening and includes a detailed table that compares the current manual practice with the modified processes resulting from implementation of various automated systems (Cytyc's ThinPrep, AccuMed's AcCell/TracCell, NeoPath's AutoPap QC and AutoPap Screener, and NeuroMedical's PapNet). The following information is from a summary table in the article. Table II: Net Change in Cost per Test Automated System Change in cost per test ($) PAPNET +18.67 AutoPap QC +3.29 ThinPrep +3.18 AutoPap Screener +3.14 AcCell Cytopathology System -0.68 If you would like to receive a copy of the article, please let me know via e-mail (ir@accumed.com). (If you have requested an Investor Pack within the last few days, a copy will be included in the package.) Dana Winrow Investor Relations AccuMed International, Inc.